Research graph
References from Venetoclax consolidation deepens response and enables measurable residual disease–guided finite therapy in BTK inhibitor–treated chronic lymphocytic leukemia. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmoa1215637
10.1056/nejmoa1215637 · External reference
10.1200/jco.21.01210
10.1200/jco.21.01210 · External reference
10.1056/nejmoa1812836
10.1056/nejmoa1812836 · External reference
Zanubrutinib versus bendamustine and rituximab in untreated CLL/SLL (SEQUOIA): a randomized, controlled, phase 3 trial
10.1016/s1470-2045(22)00293-5 · 2022 · External reference
10.1056/nejmoa1713976
10.1056/nejmoa1713976 · External reference
10.1056/nejmoa1815281
10.1056/nejmoa1815281 · External reference
10.1182/blood.2024024631
10.1182/blood.2024024631 · External reference
10.1056/nejmoa1900574
10.1056/nejmoa1900574 · External reference
10.1200/jco.21.00807
10.1200/jco.21.00807 · External reference
10.1056/evidoa2200006
10.1056/evidoa2200006 · External reference
10.1038/s41375-023-01901-4
10.1038/s41375-023-01901-4 · External reference
10.1182/blood-2024-201555
10.1182/blood-2024-201555 · External reference
10.1038/leu.2012.216
10.1038/leu.2012.216 · External reference
10.1038/s41375-021-01241-1
10.1038/s41375-021-01241-1 · External reference
10.1182/blood-2017-09-806398
10.1182/blood-2017-09-806398 · External reference
10.1182/blood-2015-08-634816
10.1182/blood-2015-08-634816 · External reference
